Skip to content

Jazz Pharmaceuticals JAZZ Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation

Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$198.88M-999%

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
Jazz Pharmaceuticals (JAZZ) reported cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation of $452.4M in Q1 2026.
How has Jazz Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation changed year-over-year?
Jazz Pharmaceuticals's cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation increased by 182.1% year-over-year, from -$551M to $452.4M.
What does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation mean?
The total increase or decrease in the company's cash and restricted cash balance.
How do you interpret cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation?
A positive change indicates net cash generation, while a negative change indicates cash consumption.
How does cash, cash equivalent, restricted cash, and restricted cash equivalent, period increase (decrease), including exchange rate effect and discontinued operation compare across companies?
Standard reconciliation metric on the statement of cash flows.